Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study ; volume:39 ; number:7 ; day:11 ; month:5 ; year:2022 ; pages:3146-3158 ; date:7.2022
Advances in therapy ; 39, Heft 7 (11.5.2022), 3146-3158, 7.2022
- Creator
-
Cornberg, Markus
Ahumada, Adriana
Aghemo, Alessio
Andreoni, Massimo
Bhagat, Abhi
Butrymowicz, Isabel
Carmiel, Michal
Chodick, Gabriel
Conway, Brian
Song, Yanna
Gasbarrini, Antonio
Hüppe, Dietrich
Plaza, Francisco Jorquera
Lampertico, Pietro
Alonso, Maria Luisa Manzano
Myles, Lindsay
Persico, Marcello
Ramji, Alnoor
Sarrazin, Christoph
Villa, Erica
Weil, Clara
Otano, Juan Isidro Uriz
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-022-02158-6
- URN
-
urn:nbn:de:101:1-2022082009522779863067
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cornberg, Markus
- Ahumada, Adriana
- Aghemo, Alessio
- Andreoni, Massimo
- Bhagat, Abhi
- Butrymowicz, Isabel
- Carmiel, Michal
- Chodick, Gabriel
- Conway, Brian
- Song, Yanna
- Gasbarrini, Antonio
- Hüppe, Dietrich
- Plaza, Francisco Jorquera
- Lampertico, Pietro
- Alonso, Maria Luisa Manzano
- Myles, Lindsay
- Persico, Marcello
- Ramji, Alnoor
- Sarrazin, Christoph
- Villa, Erica
- Weil, Clara
- Otano, Juan Isidro Uriz
- SpringerLink (Online service)
Other Objects (12)
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Myelodysplastic syndrome in a patient with HCV cirrhosis. Case report
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Myelodysplastic syndrome in a patient with HCV cirrhosis. Case report
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Myelodysplastic syndrome in a patient with HCV cirrhosis. Case report
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection